Thyroid disease and the heart

Circulation

Volumn 116, Issue 15, 2007, Pages 1725-1735

  Klein, Irwin ^a,b,c   Danzi, Sara ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Heart failure; Hyperthyroidism; Hypothyroidism; Tachyarrhythmias; Thyroid

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DISOPYRAMIDE; GLUCOCORTICOID; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; PREDNISONE; THIOUREA; THYROID HORMONE; WARFARIN;

BLEEDING; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; EUTHYROIDISM; HEART; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART RHYTHM; HEMODYNAMICS; HORMONE ACTION; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTENSION; HYPOTHYROIDISM; LIPID METABOLISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SHOCK; THROMBOEMBOLISM; THYROID DISEASE; THYROID FUNCTION; VASCULAR RESISTANCE;

CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HEART; HUMANS; MYOCYTES, CARDIAC; RENIN-ANGIOTENSIN SYSTEM; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID HORMONES;

EID: 35148895083     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.678326     Document Type: Review

References (118)

1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-509.
2. Dillmann WH. Cellular action of thyroid hormone on the heart. Thyroid. 2002;12:447-452.
3. Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Minerva Endocrinologica. 2004;29:139-150.
4. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocrine Rev. 2005;26:704-728.
5. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab. 2002;87:968-974.
6. Klein I. Endocrine disorders and cardiovascular disease. In: Zipes DP, Libby P, Bonow R, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, Pa. W.B. Saunders; 2005:2051-2065.
7. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-530.
8. Volpe R. Immunoregulation in autoimmune thyroid disease. Thyroid. 1994;4:373-377.
9. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3-126.
10. Levey GS, Klein I. Disorders of the thyroid. In: Stein's Textbook of Medicine, 2nd ed. Boston, Mass; Little Brown & Co.: 1994;1383.
11. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238.
12. Brent G. The molecular basis of thyroid hormone action. N Engl J Med. 1994;331:847-853.
13. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest. 2005;115:2524-2533.
14. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Rev. 2002;23:38-89.
15. Everts ME, Verhoeven FA, Bezstarosti K, Moerings EP, Hennemann G, Visser TJ, Lamers JM. Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology. 1996;137:4235-4242.
16. Lazar MA, Chin WW. Nuclear thyroid hormone receptors. J Clin Invest. 1990;86:1777-1782.
17. Wu Y, Koenig RJ. Gene regulation by thyroid hormone. Trends Endocrinol Metab. 2000;11:207-211.
18. Danzi S, Dubon P, Klein I. Effect of serum T3 on the regulation of cardiac gene expression: role of histone acetylation. Am J Physiol Heart Circ Physiol. 2005;289:1506-1511.
19. Haddad F, Bodell PW, Qin AX, Giger JM, Baldwin KM. Role of antisense RNA in coordinating cardiac myosin heavy chain gene switching. J Biol Chem. 2003;278:37132-37138.
20. Hu X, Lazar MA. Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab. 2000;11:6-10.
21. Hartong R, Wang N, Kurokawa R, Lazar MA, Glass CK, Apriletti, Dillmann WH. Delineation of three different thyroid hormone-response elements in promoter of rat sarcoplasmic reticulum Ca2+-ATPase gene. J Biol Chem. 1994;269:13021-13029.
22. Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab. 1991;73:146-150.
23. Kiss E, Jakab G, Kranias EG, Edes I. Thyroid hormone-induced alterations in phospholamban protein expression: regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res. 1994;75:245-251.
24. Klemperer J, Klein I, Gomez M, Helm R, Ojamaa K, Thomas S, Isom OW, Krieger K. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333:1522-1527.
25. Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid. 2002;12:459-466.
26. Hiroi Y, Kim H-H, Ying H, Furuya F, Huang Z, Simoncini T, Noma K, Ueki K, Nguyen N-H, Scanlan TS, Moskowitz MA, Cheng S-Y, Liao JK. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A. 2006;103:14104-14109.
27. Park K, Dai H, Ojamaa K, Lowenstein E, Klein I, Sellke F. Direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg. 1997;85:734-738.
28. Crowley WF Jr, Ridgway EC, Bough EW, Francis GS, Daniels GH, Kourides IA, Myers GS, Maloof F. Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med. 1977;296:1-6.
29. Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, Alvarez-Guerra M, Garcia-Estan J. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006;154:197-212.
30. Napoli R, Biondi B, Guardasole V, Matarazzo M, Pardo F, Angelini V, Fazio S, Sacca L. Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation. 2001;104:3076-3080.
31. Kuzman JA, Gerdes AM, Kobayashi S, Liang Q. Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2005;39:841-844.
32. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Chiadoni L, Salvetti A, Ferrannini E, Monzani F. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003;88:3731-3737.
33. Imai T, Hirata Y, Iwashina M, Marumo F. Hormonal regulation of rat adrenomedullin gene in vasculature. Endocrinology. 1995;136:1544-1548.
34. Diekman MJ, Harms MP, Endert E, Wieling W, Wiersinga WM. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol. 2001;144:339-346.
35. Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens. 2003;16:407-415.
36. Marcisz C, Jonderko G, Kucharz EJ. Influence of short-time application of a low sodium diet on blood pressure in patients with hyperthyroidism or hypothyroidism during therapy. Am J Hypertens. 2001;14:995-1002.
37. Lewicki JA, Protter AA. Physiological studies of the natriuretic peptide family. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press; 1995:1029-1053.
38. Fish SA, Mandel SJ. The blood in thyrotoxicosis. In: Braverman L, Utiger R, eds. Werner and Ingbar's The Thyroid. 9th ed. Philadelphia, Pa: Lippincott-Raven Publishers; 2005:595-598.
39. Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A. 1992;89:5251-5255.
40. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest. 1997;100:2362-2370.
41. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997;100:2315-2324.
42. Danzi S, Klein I, Portman M. Effect of triiodothyronine on gene transcription during cardiopulmonary bypass in infants with ventricular septal defect. Am J Cardiol. 2005;95:787-789.
43. Klein I, Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest. 1986;77:1694-1698.
44. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, Filetti S, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85:4701-4705.
45. Dorr M, Wolff B, Robinson DM, John U, Ludemann J, Meng W, Felix SB, Volzke H. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab. 2005;90:673-677.
46. Bahouth SW, Cui X, Beauchamp MJ, Park EA. Thyroid hormone induces beta1-adrenergic receptor gene transcription through a direct repeat separated by five nucleotides. J Mol Cell Cardiol. 1997;29:3223-3237.
47. Sun Z, Ojamaa K, Coetzee WA, Artman M, Klein I. Effects of thyroid hormone on action potential and repolarization currents in rat ventricular myocytes. Am J Physiol Endocrinol Metab. 2000;278:E302-E307.
48. Shi W, Wymore R, Yu H, Wu J, Wymore RT, Pan Z, Robinson RB, Dixon JE, McKinnon D, Cohen IS. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res. 1999;85:e1-e6.
49. Pachucki J, Burmeister LA, Larsen PR. Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circ Res. 1999;85:498-503.
50. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke. 1988;19:15-18.
51. Hoit BD, Khoury SF, Shao Y, Gabel M, Ligget SB, Walsh RA. Effects of thyroid hormone on cardiac b-adrenergic responsiveness in conscious baboons. Circulation. 1997;96:592-598.
52. Ventrella S, Klein I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. The Endocrinologist. 1994;4:391-399.
53. Asvold BO, Bjoro T, Nilsen T, Vatten LJ. Association between blood pressure and serum TSH concentration within the reference range: a population-based study. J Clin Endocrinol Metab. 2007;9:841-845.
54. Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Curr Hypertens Rep. 2003;5:513-520.
55. Volzke H, Alte D, Dorr M, Wallaschofski H, John U, Felix SB, Rettig R. The association between subclinical hyperthyroidism and blood pressure in a population-based study. J Hypertens. 2006;24:1947-1953.
56. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction and blood pressure: a community-based study. Clin Endocrinol. 2006;65:486-491.
57. Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: a secondary cause of isolated systolic hypertension. J Clin Hypertens. 2006;8:596-599.
58. Palmieri EA, Fazio S, Palmieri V, Lombardi G, Biondi B. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade. Eur J Endocrinol. 2004;150:757-762.
59. Merce J, Ferras S, Oltra C, Sanz E, Vendrell J, Simon I, Camprubi M, Bardaji A, Ridao C. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med. 2005;118:126-133.
60. Marvisi M, Zambrelli P, Brianti M, Civardi G, Lampugnani R, Delsignore R. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur J Intern Med. 2006;17:267-271.
61. Paran Y, Nimrod A, Goldin Y, Justo D. Pulmonary hypertension and predominant right heart failure in thyrotoxicosis. Resuscitation. 2006;69:339-341.
62. Ma RC, Cheng AY, So WY, Hui DS. Thyrotoxicosis and pulmonary hypertension. Am J Med. 2005;118:927-928.
63. Curnock AL, Dweik RA, Higgins BH, Saadi HF, Arroliga AC. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci. 1999;318:289-292.
64. Duntas LH. Thyroid disease and lipids. Thyroid. 2002;12:287-293.
65. Evered DC, Ormston BJ, Smith PA, Hall R, Bird T. Grades of Hypothyroidism. BMJ. 1973;1:657-662.
66. Staub JJ, Althaus BU, Engler H, Ryff AS, Trabucco P, Marquardt K, Burckhardt D, Girard J, Weintraub BD. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med. 1992;92:631-642.
67. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function and quality of life in subclinical hypothyroidism: randomised, crossover trial. J Clin Endocrinol Metab. 2007;92:1715-1723.
68. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab. 2002;87:1533-1538.
69. Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJ, Myant NB. Defects of receptor-mediated low-density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci U S A. 1981;78:2591-2595.
70. Rush J, Danzi S, Klein I. Role of thyroid disease in the development of statin-induced myopathy. The Endocrinologist. 2006;16:279-285.
71. Drover VAB, Agellon LB. Regulation of the human cholesterol 7 α-hydroxylase gene (CYP7A1) by thyroid hormone in transgenic mice. Endocrinology. 2004;145:574-581.
72. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270-278.
73. Forfar JC, Muir AL, Sawyers SA, Toft AD. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N Engl J Med. 1982;307:1165-1170.
74. Olsen B, Klein I, Benner R, Burdett R, Trzepacz P, Levey GS. Hyperthyroid myopathy and the response to treatment. Thyroid. 1991;1:137-141.
75. Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. 2000;68:750-755.
76. Choi YH, Chung JH, Bae SW, Lee WH, Jeong EM, Kang MG, Kim BJ, Kim KW, Park JE. Severe coronary artery spasm can be associated with hyperthyroidism. Coron Artery Dis. 2005;16:135-139.
77. Im SH, Oh CW, Kwon OK, Kim JE, Han DH. Moyamoya disease associated with Graves disease: special considerations regarding clinical significance and management. J Neurosurg. 2005;102:1013-1017.
78. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular symptoms and cardiac rate and rhythm abnormalities improve with treatment in patients with hyperthyroidism. J Am Coll Cardiol. 2007;49:71-81.
79. Cacciatori V, Bellavere F, Pezzarossa A, Dellera A, Gemma ML, Thomaseth K, Castello R, Moghetti P, Muggeo M. Power spectral analysis of heart rate in hyperthyroidism. J Clin Endocrinol Metab. 1996;81:2828-2835.
80. Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease: influence of age on clinical findings. Arch Intern Med. 1988;148:626-631.
81. Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K, Hardman SM. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J. 2000;21:327-333.
82. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142:838-842.
83. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med. 2004;164:1675-1678.
84. Krahn AD, Klein GJ, Kerr CR, Boone J, Sheldon R, Green M, Talajic M, Wang X, Connolly S. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med. 1996;156:2221-2224.
85. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med. 1994;121:281-288.
86. Kim D, Smith TW. Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells. J Clin Invest. 1984;74:1481-1488.
87. Roti E, Montermini M, Roti S, Gardini E, Robuschi G, Minelli R, Salvi M, Bentivoglio M, Guiducci U, Braverman LE. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med. 1988;148:1919-192.
88. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A; American College of Cardiology/ American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. J Am Col Cardiol. 2001;38:1231-1266.
89. Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid. 2002;12:489-493.
90. Evangelopoulou ME, Alevizaki M, Toumanidis S, Piperingos G, Mavrikakis M, Sotou D, Evangelopoulou K, Koutras DA. Mitral valve prolapse in autoimmune thyroid disease: an index of systemic autoimmunity? Thyroid. 1999;9:973-977.
91. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252.
92. Delit C, Silver S, Yohalem SB, Segal RL. Thyrocardiac disease and its management with radioactive iodine I-131. JAMA. 1961;29:262-267.
93. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;38:712-718.
94. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294:71-80.
95. Steinberg AD. Myxedema and coronary artery disease: a comparative autopsy study. Ann Intern Med. 1968;68:338-344.
96. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003;88:2438-2444.
97. Qureshi AI, Suri FK, Nasar A, Kirmani JF, Divani AA, Giles WH. Free thyroxine index and risk of stroke: results from the National Health and Nutrition Examination Survey Follow-up Study. Med Sci Monit. 2006;12:CR501-CR506.
98. Palmieri EA, Fazio S, Lombardi G, Biondi B. Subclinical hypothyroidism and cardiovascular risk: a reason to treat? Treat Endocrinol. 2004;3:233-244.
99. Fredlund BO, Olsson SB. Long QT interval and ventricular tachycardia of "torsade de pointe" type in hypothyroidism. Acta Med Scand. 1983;213:231-235.
100. Belke DD, Gloss B, Swanson EA, Dillmann WH. Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms {alpha}1 and {beta}1 improves contractile function in pressure overload-induced cardiac hypertrophy. Endocrinology. 2007;148:2870-2877.
101. Khaleeli AA, Memon N. Factors affecting resolution of pericardial effusions in primary hypothyroidism: a clinical Postgrad Med J. 1982;58:473-476.
102. Keating FR Jr, Parkin TW, Selby JB, Dickinson LS. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis. 1961;3:364-381.
103. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358:861-865.
104. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295:1033-1041.
105. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, Muller B. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind placebo-controlled trial. Atherosclerosis. 2003;166:379-386.
106. Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med. 2006;119:541-551.
107. Schmidt-Ott UM, Ascheim DD. Thyroid hormone and heart failure. Curr Heart Fail Rep. 2006;3:114-119.
108. Pingitore A, Landi P, Taddei MC, Ripoli A, L'Abbate A, Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118:132-136.
109. Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol. 1990;16:91-95.
110. Katzeff HL, Powell SR, Ojamaa K. Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am J Physiol. 1997;273:E951-E956.
111. Amico JA, Richardson V, Alpert B, Klein I. Clinical and chemical assessment of thyroid function during therapy with amiodarone. Arch Intern Med. 1984;144:487-490.
112. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 2006;126:63-73.
113. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22:240-254.
114. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Tanda ML, Dell'Unto E, Aghini-Lombardi F, Martino E. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab. 2007;92:556-562.
115. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results from a prospective study. J Clin Endocrinol Metab. 1996;81:2930-2933.
116. Diehl LA, Romaldini JH, Graf H, Bartalena L, Martino E, Albino CC, Wiersinga WM. Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. Clin Endocrinol. 2006;65:433-438.
117. Davies PH, Franklyn JA, Sheppard MC. Treatment of amiodarone induced thyrotoxicosis with carbimazole alone and continuation of amiodarone. BMJ. 1992;305:224-225.
118. Williams M, Lo Gerfo P. Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid. 2002;12:523-525.